Search Results 771-780 of 17003 for pharmacogenetics
ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...
Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy ...
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the ...
There is evidence that colonic inflammation plays a major role in colon polyp and colorectal cancer development. For example, inflammatory bowel disease is a ...
Studies conducted by Mayo investigators have found associations between burnout and medical error, medical malpractice litigation, decreased productivity and ...
The purpose of this study is to demonstrate that WC and WHR measurements are non-inferior to HW on patient-reported comfort. Non-inferiority is declared if the ...
Inclusion Criteria: Healthy individuals 18 years of age or older. Exclusion Criteria: Individuals unable to walk without a walking aid.
About this study. RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer.
The purpose of this study is to evaluate the safety of using iluvien to treat patients with diabetic macular edema, by assessing intraocular pressure.
Review the student roster and career outcomes of the Predoctoral Training Program in Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!